“Glucagon-Like Peptide Receptor Agonists (GLP-1 Receptor agonists): A Powerful Addition to Foundational Therapy Kidney Care in Patients With Type 2 Diabetes Mellitus”. Canadian Diabetes & Endocrinology Today, vol. 2, no. 3, Nov. 2024, pp. 33–37, https://doi.org/10.58931/cdet.2024.2333.